<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929265</url>
  </required_header>
  <id_info>
    <org_study_id>IIL INFL09</org_study_id>
    <nct_id>NCT01929265</nct_id>
  </id_info>
  <brief_title>A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma</brief_title>
  <acronym>IIL INFL09</acronym>
  <official_title>A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety
      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with
      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety
      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with
      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).

      The study includes and induction phase and a consolidation phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate (CR)</measure>
    <time_frame>5 months</time_frame>
    <description>Evaluated at the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety analysis</measure>
    <time_frame>5 months</time_frame>
    <description>Evaluated during and at the end of treatment. Percentage of patients with adverse, hematological and non-hematological toxic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>5 months</time_frame>
    <description>Evaluated at the end of treatment. Complete plus partial remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Progression, relapse or dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (PFS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Relapse or dead for any causes from the end of treatment, for patients in CR after B+R. Evaluated by means of Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Indolent Non-follicular</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab - Bendamustine (RB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 arm: Rituximab - Bendamustine (RB)
1 arm for all patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>INDUCTION PHASE
Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):
Rituximab: 375 mg/sqm iv, day 1*
Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice
Repeat cycles every 28 days for a total of 4 cycles
*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.
CONSOLIDATION PHASE
Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):
Rituximab: 375 mg/sqm iv day 1
Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice
Rituximab two monthly doses
Rituximab: 375 mg/sqm iv week 24 and 28</description>
    <arm_group_label>Rituximab - Bendamustine (RB)</arm_group_label>
    <other_name>RIBOMUSTIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand and voluntarily sign an informed consent form

          2. Histological (bone marrow or lymph nodes biopsy) proven diagnosis of B-cell CD20-
             positive non-follicular NHL according to REAL/WHO Classification:

             i. small lymphocytic lymphoma-SLL (bone marrow or lymph nodes biopsy ii.
             lymphoplasmacytic/citoid lymphoma/ Waldenstrom macroglobulinemia(bone marrow or lymph
             nodes biopsy) iii. nodal marginal zone lymphoma (lymph nodes biopsy)

          3. Untreated patients

          4. Stage III or IV or stage II with more than three involved sites

          5. Presence of at least one of the following criteria for the definition of active
             disease:

               1. Systemic symptoms

               2. Hemoglobin less than 10 g/dL (due to lymphoma)

               3. Platelets less than 100 x 10 9/L (due to lymphoma)

               4. Diffuse bone marrow infiltrate

               5. Lymphocyte doubling time less than 12 months (in leukemic cases)

               6. Bulky disease (&gt;7 cm)

          6. Aged 18 - 75 Life expectancy &gt;6 months

          7. ECOG performance status 0-2

          8. LVEF ≥45% or FS ≥37%

          9. ANC ≥1 x 10 9/l and Platelets count ≥75 x 10 9/l, unless due to bone marrow
             involvement by follicular lymphoma

         10. Creatinine up to 1.5 x ULN

         11. Conjugated bilirubin up to 2 x ULN

         12. Alkaline phosphatase and transaminases up to 2 x ULN

         13. Written informed content

        Exclusion Criteria:

          1. Patients with diagnosis of marginal zone lymphoma of splenic or MALT origin

          2. Patients with diagnosis of typical Chronic Lymphocytic Leukemia (CLL)

          3. Men not agreeing to take adequate contraceptive precautions during and for at least 6
             months after cessation of therapy

          4. History of other malignancies within 3 years prior to study entry except for:
             adequately treated carcinoma in situ of the cervix; basal or squamous cell skin
             cancer; low grade, early stage, localized prostate cancer treated surgically with
             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with
             curative intent

          5. Medical condition requiring long term use (&gt;1 months) of systemic corticosteroids

          6. Active bacterial, viral, or fungal infection requiring systemic therapy

          7. Concurrent medical condition which might exclude administration of therapy

          8. Cardiac insufficiency (NYHA grade III/IV)

          9. Myocardial infarction within 6 months of entry on study

         10. Severe chronic obstructive pulmonary disease with hypoxemia

         11. Severe diabetes mellitus difficult to control with adequate insulin therapy

         12. Hypertension that is difficult to control

         13. Impaired renal function with creatinine clearance &lt;30 ml/min

         14. HIV positivity

         15. HBV positivity with the exception of patients HbsAg negative and Ab anti-Hbcore
             positive(these patientes need to receive prophylaxis with Lamivudine)

         16. HCV positivity with the exception of patients with HCV RNA negative.

         17. CNS involvement by lymphoma

         18. Participation at the same time in another study in with investiogational drugs are
             used

         19. Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins

         20. Any other co-existing medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent

         21. Women in pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Baldini, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SC Ematologia - AO SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e Trapianti, Ospedale San Maurizio</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Centro Trapianto di Cellule Staminali</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia I , Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia Azienda Ospedaliera Papardo</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Azienda Ospedaliero Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. Oncologia Medica - CRO, Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia Istituto Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Università - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Santo Spirito</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOA Ematologia, Ospedale Civile Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. Ematologia AO Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia, Azienda Ospedaliera Arcispedale &quot;S.Maria Nuova&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia, Università &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologia Policlino Le Scotte</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Onco-Ematologia Azienda Ospedaliera S.Maria</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia - Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia U - Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica e Unità di Terapie Cellulari 'Carlo Melzi' AOU S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INFL</keyword>
  <keyword>Indolent non-follicular</keyword>
  <keyword>untreated INFL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

